Page last updated: 2024-12-06

nsc 338720

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

penclomedine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60203
CHEMBL ID273124
SCHEMBL ID188460
MeSH IDM0162840

Synonyms (23)

Synonym
NCI60_002989
NCIMECH_000533
pyridine,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)-
nsc-338720
108030-77-9
NSC338720 ,
penclomedine
pyridine, 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)-
nsc 338720
3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine
CHEMBL273124
ccris 9406
unii-66q80il7cw
66q80il7cw ,
CCG-35550
SCHEMBL188460
3,5-dichloro-2,4-dimethyloxy-6-trichloromethyl-pyridine
penclomedine [who-dd]
3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine #
nsc 338720; pen
DTXSID50148365
DB12987
Q27264013

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic assessment was performed during the first cycle of treatment."( Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.
Alberti, D; Arzoomanian, RZ; Berlin, J; Feierabend, C; Simon, K; Stewart, JA; Storer, B; Tutsch, KD; Wilding, G, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of penclomedine ranged from 28% to 98% (median 73%)."( Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
Bowling, KM; Collins, J; Donehower, RC; Hartman, NR; O'Reilly, S; Rowinsky, EK; Strong, JM, 2001
)
0.31
" Formulations with particle size 160 nm had the highest relative bioavailability (set at F=1), whereas administration in particle size 720 nm had slightly lower bioavailability (F=0."( Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility.
Campanero, MA; de Smidt, PC; Trocóniz, IF, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
"On a 1-hour dosing schedule, ataxia, vertigo, nystagmus, and a motor aphasia were the principal toxicities of penclomedine."( Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
Bowling, K; Chen, TL; Donehower, RC; Grochow, LB; Hartman, NR; O'Reilly, S; Rowinsky, EK; Struck, RF, 1997
)
0.3
" on a dailyx5-day dosing schedule."( The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum.
Molliver, ME; O'Hearn, E; O'Reilly, S; Rowinsky, EK; Struck, RF, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID121289Tumor growth delay in comparison vehicle-treated control, difference in the median time poststaging for tumors of the treated (T) group to double twice in mass compared to the median of the control (C) group ce2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites.
AID124605Number of tumor-free survivors in a group of five mice2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites.
AID117482In vivo optimal (ip) dosage (<LD10) against subcutaneously implanted human mammary tumor xenograft MX-1 on a five-successive day schedule in Athymic NCr-nu/nu mice2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis and antitumor activity of several new analogues of penclomedine and its metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.17)18.7374
1990's13 (54.17)18.2507
2000's10 (41.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (19.23%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (80.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]